MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'daiichi'. Sat, 03 Sep 2011 02:32:26 +0100 http://www.medworm.com/index.php?rid=5140261&cid=t_188899_147_f&fid=39273&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FePharmaSummit%2F%7E3%2FFWhQjNwuZeQ%2Fepharma-west-measuring-roi-and.html Mix/Channel Optimization: Integrating your Resources to Enhance Productivity Scott Wearley, Manager, Relationship Marketing, Daiichi Sankyo Wearley found that oftentimes the wrong resources sales reps were provided went unutilized or the resources are reaching the wrong person. The effectiveness of the individual sales campaigns, as a result, goes down. Management of the resources we currently have are not optimal. Do the samples go to the right physicians? Sit down with the sales representatives and look at the data from sales to determine what is the best approach to reaching the physicians they are working with. Digital promotions that are increasing thanks to the iPad offer a great complement to their work face-to-face sales relationships. Digital promotion does not need to destroy ... ePharma Summit blogs http://www.medworm.com/rss/comments.php?id=5140261 Mon, 25 Jul 2011 23:59:00 +0100 5140261 http://www.medworm.com/index.php?rid=4893917&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FaIPonxw6_os%2F One year after an analysis of five studies involving some 60,000 patients found links between angiotensin receptor blockers and an increased risk of cancer, the FDA has now decided that these meds - which are used to control high blood pressure, do not pose such a risk. The study, which was published in The Lancet Oncology and prompted the FDA review, found that 7.2 percent of patients on an ARB were diagnosed with cancer compared with 6 percent on a placebo, which was deemed statistically significant. Put another way: one extra cancer case would occur for every 105 people taking the meds for about four years (back story). Most of the patients were taking Boehringer Ingelheim’s Micardis, a $1.5 billion seller, prompting an angry rebuttal from the drugmaker. Other ARBs that were studied i... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4893917 Thu, 02 Jun 2011 19:21:10 +0100 4893917 http://www.medworm.com/index.php?rid=4803521&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FNOAZICn26TY%2F About 120 full-time and 30 part-time employees of Zenotech Laboratories - which was controlled by Ranbaxy Laboratories before Daiichi Sankyo bought the Indian drugmaker - have gone on an “indefinite strike” because they claim they were not paid salaries last month and management has gone back on its word about marketing Zenotech products, according to reports from India. Apparently, production has been stopped in the Zenotech plant in Hyderabad and research and development operations were suspended for a third straight day. Zenotech makes 13 products including three biotech and 10 oncology products. Through its acqusition of Ranbaxy, Daiichi holds nearly 67 percent in Zenotech. “We have three key demands. These include an assured annual business Rs15 crore a year as promised ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4803521 Tue, 10 May 2011 13:54:43 +0100 4803521 http://www.medworm.com/index.php?rid=4693507&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FvHycW-dgqLw%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is our regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that QuantumMethod has hired Michele McHugh-Mazzatta, as a partner and she will manage east coast operations. Before joining the marketing firm, she ran her own firm, Four M Group, and previously spent more than 20 years at GlaxoSmithKline, most rec... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4693507 Fri, 08 Apr 2011 12:00:11 +0100 4693507 http://www.medworm.com/index.php?rid=4606052&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FFiK0SOKwv4Q%2F Where, oh where, did your health care budget go? A larger chunk apparently went to pay for brand-name* prescription meds which, on average, rose 6.9 percent last year. The increase nudged past the 6.8 percent average advance registered in 2008, which was the largest annual jump since Barclays Capital began tracking price hikes, The Wall Street Journal reports. Some of the biggest: the Benicar blood pressure pill sold by Daiichi Sankyo rose 29.3 percent; the Gleevec cancer treatment marketed by Novartis jumped 20.9 percent; Johnson & Johnson’s Concerta pill for ADD moved up 19.7 percent; Pfizer’s Lipitor cholesterol blockbuster popped 12.4 percent, and the Plavix bloodthinner sold by Bristol-Myers Squibb and Sanofi-Aventis rose 13.2 percent. Obviously, drugmakers are &#8220... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4606052 Thu, 17 Mar 2011 12:15:48 +0100 4606052 http://www.medworm.com/index.php?rid=4592693&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F7yeu7oUAR0E%2F Good morning, everyone, and nice to see you again. A bumpy ride today as we labored to hustle the short people off to the school house. Nonetheless, we survived and this calls, of course, for a cup or two of much-needed stimulation. Please join us. Meanwhile, here are a few tidbits we came across. If you have a chance, let us know about anything else that appears interesting. Have a great day… Novartis Blood Cancer Drug Meets Study Goal (Reuters) Whistleblowers And Smear Lawsuits (Nature News) Daiichi Has Still Not Gained From Buying Ranbaxy (Wall Street Journal) US Drug Prices Outpaced Other Medical Costs: GAO (Reuters) A Link Between Sunlight And Drug Efficacy Is Found (InPharma Technologist) Australia Blocks Subsidies For New Drugs (Pharma Times) Labopharm CEO Steps Down Amid Revi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4592693 Tue, 15 Mar 2011 12:12:54 +0100 4592693 http://www.medworm.com/index.php?rid=4575247&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F0Udf2nUwwkU%2F And so another working week will soon draw to a close. This, of course, means that the time has come to daydream about weekend plans. Our agenda is rather modest - we hope to do fun things with assorted short people, catch up on some sleep and read interesting documents about a big drugmaker (this can actually be relaxing). What about you? Will you cavort with a special someone? Run some errands? Make plans to escape somewhere? Whatever your fancy, be safe and enjoy. Meanwhile, here a few tidbits. See you soon… Merck Not Obligated To Accept Bid For Dutch Organon Unit (Dow Jones) Amgen Will Buy Pfizer Plant In Ireland (Bloomberg News) Arena Pharma Narrows Losses (Associated Press) Roche’s Accutane Caused Tragedy For An Actor (Bloomberg News) Dendreon Gets OK To Expand Provenge C... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4575247 Fri, 11 Mar 2011 12:37:29 +0100 4575247 http://www.medworm.com/index.php?rid=4532570&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F8IsrwzAqM_A%2F Top of the morning to you. A sunny day is unfolding here on the Pharmalot corporate campus, where we are, once again, hustling short people off to this or that school house. Nonetheless, we are also reaching for our mandatory cup of stimulation - our flavor today is Cinnamon Cream Swirl - and looking about for interesting items. Please let us know if you spot something yourself. Meanwhile, have a great day… Daiichi To Buy Plexxicon For Up To $935M (Bloomberg News) Pharma Job Outlook Bleak In Europe As Sites Are Closed (Reuters) Forest And Nycomed Win FDA Approval For COPD Drug (Associated Press) Elan Pleads Guilty In Zonegran Marketing (Boston Business Journal) Feds Award $215M For Flu Vaccine Development (Associated Press) UK’s NICE Wants More Data On Roche Cancer Drug (Dow Jo... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4532570 Tue, 01 Mar 2011 13:02:23 +0100 4532570 http://www.medworm.com/index.php?rid=4406035&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FWUnyPvea7wM%2F Just five months after Atul Sobti resigned as ceo of Ranbaxy Laboratories, the Indian drugmaker told the Bombay Stock Exchange that Omesh Sethi had resigned as president and chief financial officer. The move comes as Ranbaxy continues to struggle to correct manufacturing problems and has undergone repeated managerial overhauls. Early last year, the FDA determined Ranbaxy sold misbranded or adulterated drugs in the US, its largest market, and halted approvals at two plants in India, after previoulsy banning imports of over 30 generic drugs (see this and this). There is still no mention on the Ranbaxy web site, however, of the departure and no official statement offering any explanation for the turn of events. But the resignation becomes yet another headache for Daiichi Sankyo, which paid $4... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4406035 Thu, 27 Jan 2011 13:12:40 +0100 4406035 http://www.medworm.com/index.php?rid=4119716&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F_uKvTFMX99I%2F Rise and shine, everyone. Another day beckons. And this is a special one here on the Pharmalot corporate campus as the shortest of short people celebrates a birthday. An especially large cup of stimulation is in order…among other things. While we fuss, please enjoy these items and, of course, we hope your weekend is wonderful. Whether you pick a pumpkin, rake some leaves, read a book or enjoy a walk, do enjoy yourselves. See you soon… Glaxo Licenses Amicus Therapeutics’ Fabry Drug (Reuters) Sanofi-Aventis Buys A Chinese OTC Maker (Associated Press) Glaxo Cuts Prices In Indonesia By Up To 50 Percent (Reuters) Hepatitis C Is Fertile Field For Blockbusters (The Wall Street Journal) Supreme Court To Review Roche And Stanford Dispute Today (The Tech) AstraZeneca And Daiichi Sign $... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4119716 Fri, 29 Oct 2010 11:35:14 +0100 4119716 http://www.medworm.com/index.php?rid=4023133&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fp92MksnLtSA%2F For six years, Jeremy Garrity worked for Novartis promoting various cardiovascular medicines, such as Diovan and Tekturna. But he was fired in 2008 and later filed a whistleblower lawsuit, one of four that prompted the federal government to launch an investigation into off-label marketing. Yesterday, the drugmaker agreed to pay $422.5 million to settle civil and criminal charges. Garrity, who no longer works in the pharmaceutical industry, revealed in his lawsuit several interesting practices: some doctors who served as speakers read from prepared scripts; some doctors were recruited as speakers even if their English was poor; both doctor and event attendees were paid honoraria, and doctors who did not prescribe did not get paid. We spoke with the 35-year-old Garrity, who lives in the Midw... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4023133 Fri, 01 Oct 2010 18:03:01 +0100 4023133 http://www.medworm.com/index.php?rid=3903129&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FTnk_tZYOS78%2F Two years after the FDA came down hard on Ranbaxy Laboratories, the generic drugmaker is reportedly offering to make a sweeping, one-time penalty payment in hopes of convincing the agency to allow shipments of various drugs to the US to resume. Such a payment, which is usually tied to a consent decree, may constitute as much as 20 percent of revenue over the past three years. The news was reported on MoneyControl and Ranbaxy officials refused to comment, but did not deny the report (watch the video here). We await a reply from the FDA. You may recall that, two years ago, federal prosecutors cited the Indian drugmaker for allegedly falsifying records that resulted in the production and sale of meds failing to meet FDA standards. The allegations included fabricating bioequivalence and stabil... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3903129 Wed, 25 Aug 2010 13:39:56 +0100 3903129 http://www.medworm.com/index.php?rid=3862187&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FDW5ugcBhxls%2F For Daiichi-Sankyo, things keep going from bad to worse at its Ranbaxy Laboratories unit. Atul Sobti resigned today as ceo of the Indian drugmaker, which has been struggling to correct manufacturing problems and has undergone repeated managerial overhauls. Little, in fact, has gone right since Daiichi paid $4.6 billion for Ranbaxy two years ago. Sobti, who was in the job for just one year, is departing over a rift in strategy, according to reports. “Diifferent individual opinions reach a stage where you have to take a decision,” Sobti said at a news briefing in New Delhi today. Under his stewardship, Ranbaxy recently recovered from its first net loss in eight years. Seeking to spin, a Daiichi spokesman tells Bloomberg News that Sobti, 46, Sobti decided it was the “right time to s... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3862187 Thu, 12 Aug 2010 17:08:47 +0100 3862187 http://www.medworm.com/index.php?rid=3683872&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FEPyViqp86VU%2F And the answer is…. GlaxoSmithKline, which led its counterparts in a host of variables that formed the second-ever Access to Medicine Index. European drugmakers, in fact, bested US rivals in making medicines available to people in developing countries, although the foundation that runs the project says this lead is shrinking. The index is designed to offer investors a way to compare pharma’s social responsibility records by measuring 106 indicators that examined activities across seven criteria such as philanthropy, patents, pricing and management (see more here). The latest report - the first was issued in 2008 - covers 27 companies, including 20 brand-name drugmakers and seven generics manufacturers, which have their own list and was topped by Ranbaxy Labs, now owned by Daiic... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3683872 Mon, 21 Jun 2010 12:45:18 +0100 3683872 http://www.medworm.com/index.php?rid=3676896&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fpu9bdldv2LI%2F Amid ongoing quality control problems at its manufacturing facilities, Ranbaxy Laboratories will close one of its biggest global bulk drug production units in Mohali, India, and is now relying on local contractors to supply the products that have been made there, The Economic Times reports. The move appears to contradict recent statements about outsourcing. Ranbaxy, which is owned by Daiichi Sankyo, has been looking to outsource some manufacturing, but planned to restrict this to small markets. In its latest annual report, the paper notes, the drugmaker indicated it will look to outsource either products or manufacturing capacities, but only in countries outside its top 20 markets. India, of course, is one of its top markets. So why is this happening? For one, the US Pharmacopeia is upgra... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3676896 Fri, 18 Jun 2010 17:32:31 +0100 3676896 http://www.medworm.com/index.php?rid=3659157&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FjA9j-WiJtWE%2F A new analysis of five previous studies involving about 60,000 patients found links between angiotensin receptor blockers, or ARBs, which are widely used blood pressure drugs, to an increased risk of cancer. Specifically, 7.2 percent of patients on an ARB were diagnosed with cancer compared with 6 percent on a placebo, which was deemed statistically significant. The study, which was published in The Lancet Oncology, determined that one extra cancer case will occur for every 105 people taking the meds for about four years, although there isn’t enough info to know if the risk disappears after the drugs are stopped. Interestingly, there was no difference in the rate of cancer deaths in people on the drugs compared to those not on them. “The risk for the individual patient is mode... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3659157 Mon, 14 Jun 2010 12:15:47 +0100 3659157 http://www.medworm.com/index.php?rid=3607816&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F5EI31TVBif4%2F And so another week will soon draw to a close, although it will be a longer-than-usual weekend on this side of the pond. Have any interesting plans? So many choices, we know. Our own agenda includes walking the Pharmalot mascot, driving through the countryside, quaffing beverages with Mrs. Pharmalot and keeping the short and not-so-short people amused (wish us luck). Whatever you do, we hope you have a grand time. Meanwhile, here are a few items to help you speed through the day. Have a good one and see you soon… Amgen’s Prolia Osteoporosis Drug Wins EU Approval (PharmaTimes) Teva Stops Making The Propofol Sedative (Reuters) Daiichi Sankyo Is Confident About Resolving Ranbaxy Ban (Bloomberg News) Breast Cancer Patients Win Right To Sue Wyeth (Canadian Broadcasting) AstraZeneca&... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3607816 Fri, 28 May 2010 11:49:19 +0100 3607816 http://www.medworm.com/index.php?rid=3573943&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F-FkboPbzPkY%2F Daiichi Sankyo named an exec with more than 25 years of experience to oversee quality and manufacturing problems at its Ranbaxy Laboratories unit in hopes of resolving long-standing regulatory troubles. The Japanese drugmaker, which two years ago paid $4.6 billion for Ranbaxy just as the problems emerged, shifted Dale Adkisson, a quality-control veteran who has worked at Novartis and Bristol-Myers Squibb (that’s him in the mug shot), to become quality assurance director at Ranbaxy’s US offices. The move comes more than a year after the FDA banned 30 Ranbaxy drugs and halted approval of new drugs made at two plants (see this and this), causing an embarassment for Daiichi, which noted in its latest financial report that the anticipated synergies with Ranbaxy may not be achieved i... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3573943 Tue, 18 May 2010 12:46:20 +0100 3573943 http://www.medworm.com/index.php?rid=3556376&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F7Xrrvq3AF88%2F Rise and shine. Another day lies ahead. And today appears to be a bit rainy, unfortunately. Nonetheless, our spirits are sunny. Why? Once again, we enjoy repeating our favorite piece of advice from the Morning Mayor: Every brand new day should be unwrapped like a precious gift. Speaking of gifts, we would like to wish a happy birthday to Mrs. Pharmalot. Of course, you should all have a nice day. Stay in touch… Vical Cancer Drug Shows Promise In Mid-Stage Trial (Reuters) Sanofi Plans 11,000-Patient Trial Of Multaq (PharmaTimes) Daiichi Sankyo Names A New CEO (Bloomberg News) FDA Rejects Tylenol, Excedrin Study (Reuters) Key Drugs In The Merck Pipeline (Associated Press) Japanese Drugmakers’ Profits Slump (Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3556376 Wed, 12 May 2010 12:04:37 +0100 3556376 http://www.medworm.com/index.php?rid=3526947&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FGcH7rZ8YJbU%2F Another month, another list. Once again, there is speculation about which medications will generate the most revenue over the next few years. Interestingly, the latest conclusion mirrors another recent list that suggests conventional pills will easily be eclipsed. Only two small molecules make this newest ranking, which was compiled by EvaluatePharma. Not surprisingly, one of them is AstraZeneca’s Crestor cholesterol fighter, although the newest list differs slightly from this list. And so once again, there are myriad implications raised, including the strategic direction pursued by the biggest drugmakers and the costs for patients. The percentage figure refers to sales growth from 2009 to 2016… 1. Humira (arthritis) Abbott Labs/Eisai - $10.1b; 9 percent 2. Avastin (cancer) Roc... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3526947 Mon, 03 May 2010 12:47:00 +0100 3526947 http://www.medworm.com/index.php?rid=3511780&cid=t_188899_150_f&fid=38374&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FePharmaSummit%2F%7E3%2F0M0CHYvQrGo%2Fsave-date-multi-channel-pharma.html (Source: ePharma Summit) ePharma Summit blogs http://www.medworm.com/rss/comments.php?id=3511780 Wed, 28 Apr 2010 14:40:00 +0100 3511780 http://www.medworm.com/index.php?rid=3420758&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F3siamx0eDUw%2F This is a list of the top 20 drugmakers, ranked by global prescription drug sales for the 12 months ended Sept. 30, 2009, according to IMS Health, which prepared this for Reuters. The dollar sales are in billions and, next to that, is the percent change from the year-over-year period. As you can see, though, the results don’t include the mergers between Merck and Schering-Plough, and Pfizer and Wyeth, since these weren’t consummated until later in the year. 1 - Pfizer - $41.7 billion - (0.8) 2 - Novartis - $36.7 billion - 7.0 3 - Sanofi-Aventis - $35.1 billion - 3.3 4 - GlaxoSmithKline - $34.3 billion - (3.4) 5 - AstraZeneca - $33.2 billion - 7.8 6 - Roche - $31.3 billion - 8.6 7 - Johnson & Johnson - $26.9 bi... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3420758 Mon, 29 Mar 2010 16:43:51 +0100 3420758 http://www.medworm.com/index.php?rid=3311933&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FZd7KHlOccYY%2F Good morning, everyone. Another snowy day here on the Pharmalot corporate campus, where drifts are threatening to engulf our laptop. Still, we look ahead to a weekend of hot coffee, unread books and sledding with short people. Meanwhile, though, another day lies ahead. So here are a few items to help you through. What are your weekend plans? Whatever you do, enjoy. See you, soon… Daiichi Sankyo Considers Generics Market In Japan (Reuters) Merck Gets Ready To License Out Drugs (In Vivo) Pfizer Senior VP Bill Ringo To Retire (Associated Press) New Drug Prices In Australia Are Highest In Developed World (PharmaTimes) KV Pays $26M Fine For Adulterated Drugs (Bloomberg News) snowman courtesy of LD on flickr creative commons (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3311933 Fri, 26 Feb 2010 12:40:39 +0100 3311933 http://www.medworm.com/index.php?rid=3288020&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FDiabkjGOeEc%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? Inspire Pharma hired Adrian Adams as ceo and president; Cedra hired Steve Unger as vp and lab director; Patton Boggs hired Dick Thompson as a lobbyist; Liquidia Technologies hired Frank Malinoski as chief medical officer; Quanticate tapped Alison Bond to run pharmacovigilance services; BioClinica named Robert Sammis vp of finance for the eClinical unit; Bionovo appointed Pa... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3288020 Fri, 19 Feb 2010 13:07:59 +0100 3288020 http://www.medworm.com/index.php?rid=3111616&cid=t_188899_131_f&fid=35743&url=http%3A%2F%2Fthegenesherpa.blogspot.com%2F2009%2F10%2Fok-fine-back-to-plavix_4857.html Did anyone else see this?Scripps and Eric Topol are going to be doing testing for 2C19 polymorphisms in their interventional dept."Scripps physicians will initially offer the genetic tests to elective stent patients before they undergo their procedures at Scripps Green Hospital. Eventually, Scripps may extend the offering to its other facilities across San Diego County."I have been prodding Greenwich Hospital to do this.....I hope they do......They could be the El Camino of the East. What are these guys, Topol et.al going to be doing? "Scripps patients carrying the gene risk variants will be considered for three treatment choices following their stent procedures, each on an individualized basis. Patients will either: Be given a routine 75 milligram dose of Plavix with careful surveillance;... Gene Sherpas: Personalized Medicine and You blogs http://www.medworm.com/rss/comments.php?id=3111616 Fri, 09 Oct 2009 11:25:00 +0100 3111616 http://www.medworm.com/index.php?rid=1955506&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F449523793%2F Researchers have overestimated the ability to administer the experimental drug without causing dangerous bleeding, according to a prominent cardiologist, Reuters writes. Prasugrel, you may recall, has twice been delayed by the FDA, which is reportedly set to hold an advisory meeting early next year. Prasugrel is closely watched because of its blockbuster potential, although the repeated delays also symbolize the FDA’s recent caution. Lilly submitted prasugrel last December and the FDA designated a six-month priority review in February. At the end of June, FDA extended the review by another three months due to extra info given the agency. Then, the FDA missed the September 26 deadline (back story). In a closely watched clinical trial released last year, Prasugrel surpassed Plavix in preve... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1955506 Tue, 11 Nov 2008 13:10:16 +0100 1955506 http://www.medworm.com/index.php?rid=1945453&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F445430140%2F Yes, the end of the week is fast approaching. What will you do be doing after putting aside work? Raking leaves? Puttering around the house? Escaping to the movies? Whatever your fancy, we hope you have a nice time. Meanwhile, here are a few items to help you along. By the way, we will be leaving early today for an excursion with one of the short people, but will be back to keep tabs on the American Heart Association meeting… Novo Nordisk To Build Diabetes Plant In China (The Financial Times) Biovail Is Searching For Acquisitions (The Globe and Mail) India Plans Testing Zones At Airports (inPharmaTechnologist) Charles River Labs Hurt By Credit Crisis (CNBC.com) Daiichi Completes Purchase Of Ranbaxy Labs (Reuters) Glaxo Sued Over Paxil And Birth Defects (The Brampton Guardian) (Sourc... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1945453 Fri, 07 Nov 2008 12:29:59 +0100 1945453 http://www.medworm.com/index.php?rid=1888453&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F424021737%2F The agency has missed a good many deadlines for reviewing new drugs. And Reuters has been sporting enough to come up with the following list: - Prasugrel, a blood thinner from Lilly and Daiichi Sankyo. A decision was due September 26 and the application remains pending; - Promacta, a Glaxo drug for a clotting disorder. The deadline was September 19. and no decision has been made; - Nplate, a clotting disorder drug from Amgen. A decision was due July 23. The drug was approved August. 22; - Telavancin, an antibiotic from Theravance. No ruling was made at the deadline of July 21. The drug is now scheduled to go before an FDA advisory panel on November 19; - Entereg, a drug from Glaxo and Adolor to treat a complication of bowel surgery. The product was approved on May 20, which was 10 days af... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1888453 Fri, 17 Oct 2008 20:18:39 +0100 1888453 http://www.medworm.com/index.php?rid=1888460&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F423646958%2F A shiny day here on the Pharmalot corporate campus, where the leaves are quickly piling up. We look forward to a weekend of apple picking, catching up on some reading and eating a meal in our specially designed ancient hut. Meanwhile, though, the day beckons. We hope yours goes well… Daiichi Sankyo Buys 20 Percent Of Ranbaxy (Bloomberg News) FDA Reviews Main Goal Of Pozen Drug Study (Yahoo/AP) J&J Pain Drug Device Recalled (The Wall Street Journal) UK’s NICE Questions Drug Testing Methods (The Financial Times) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1888460 Fri, 17 Oct 2008 12:02:46 +0100 1888460 http://www.medworm.com/index.php?rid=1886687&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F422722216%2F Several drug and device makers are participating in a $100 million, 20,000-patient study to figure out how to protect heart patients from blood clots after being treated with stents, The Wall Street Journal reports. At issue is whether patients can safely stop using blood thinners one year after a procedure or if they should take such a med for at least two and a half years. Current guidelines call for patients who get a drug-coated stent to remain on the med for at least a year. But concern that, in rare instances, clots can form in the devices well over a year after they are implanted, with potentially lethal consequences, has left doctors and patients in a quandary over how long treatment should be prescribed, the Journal writes. “It’s created a lot of anxiety in patients&#8... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1886687 Thu, 16 Oct 2008 14:44:20 +0100 1886687 http://www.medworm.com/index.php?rid=1865682&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F414748312%2F Hello and nice to see you again. With the economic morass swirling around, there is usually one good way to avoid that gloom and doom feeling - keeping busy. So as always, we have gathered a few items to help you get started on another day. We hope this will be a good one… Roche Drug Slows Leukemia (The Wall Street Journal) Wyeth Consolidates Distribution Centers (The Richmond Times-Dispatch) FDA OKs Sanofi Renal Cancer Vaccine Trial (Reuters) Daiichi Sticks To Ranbaxy Offer Price (Bloomberg News) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1865682 Wed, 08 Oct 2008 11:30:53 +0100 1865682 http://www.medworm.com/index.php?rid=1834802&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F404143786%2F Once again, the FDA has delayed its approval of prasugrel, a blood thinner that Lilly and its partner, Daiichi Sankyo, have been hoping will one day compete against Plavix, which is marketed by Bristol-Myers Squibb and Sanofi-Aventis. This is the second time the agency has postponed approval. However, the delay last June was largely expected, given uncertainty over the increased risk of major bleeding associated with the blood thinner that was revealed in a clinical trial last November. In the study, prasugrel was pitted against Plavix and was 19 percent more effective in preventing cardiovascular death, non-fatal heart attacks and strokes. But prasugrel was 32 percent more likely to cause serious bleeding. In a brief statement, Lilly says the FDA “did not complete its review for the... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1834802 Fri, 26 Sep 2008 21:30:35 +0100 1834802 http://www.medworm.com/index.php?rid=1750395&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F379694361%2F This may be the Labor Day weekend in the US, but in Munich, leading cardiologists and pharmaceutical mavens are gathering for the annual European Society of Cardiology meeting, which began today and runs through Wednesday. Beyond the usual stream of clinical trials, the most sensational story is likely to be the final results of the Vytorin SEAS study. Preliminary data showed an unexpected linked to cancer. The full picture will be presented Tuesday morning. Meanwhile… A prescription fish-oil pill offered moderate benefits in patients with heart failure, such as lessened risk of death and hospital admissions, unlike widely prescribed cholesterol-lowering drugs called statins. In a large trial involving almost 7,000 patients in Italy, researchers found that people taking the pill - so... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1750395 Sun, 31 Aug 2008 19:17:25 +0100 1750395 http://www.medworm.com/index.php?rid=1730772&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F374190073%2F Welcome to the working week. Although this week may prove to be a bit slow here and there. It is vacation time, after all. Nonetheless, we are poking around for interesting items. So settle in and catch up with the latest… Study Finds Ideas About Sex Don’t Bar Gardasil Use (The Houston Chronicle) Pfizer Drops NicOx Glaucoma Drug For Asian Study (Yahoo/Finance) India To Review Daiichi Bid For Ranbaxy (Bloomberg News) Bristol-Myers Employees Charged With Forging Tuition Reimbursement (MyCentralNewJersey.com) Indonesian Drug Prices Soar On Raw Materials (The Jakarta Post) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1730772 Mon, 25 Aug 2008 11:26:24 +0100 1730772 http://www.medworm.com/index.php?rid=1679620&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F356263689%2F Rise and shine. ‘Tis a sunny day here in the nation’s medicine chest. And what better way to get going than to grab a cup of something stimulating and catch up on events? So we have gathered a few on your behalf. Dig in and have a great day… Wyeth Claims Retiree Lied To Get Benefits Package (LoHud.com) Daiichi Gets Regulatory OK To Buy Ranbaxy (Business Standard) Former Genentech Director Sues City Over Royalties (East Bay Business Times) Bayer Sues Sandoz Over Yaz Birth Control Pill (Bloomberg News) AstraZeneca HQ Gets Road Improvements (CommunityPub.com) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1679620 Tue, 05 Aug 2008 11:29:21 +0100 1679620 http://www.medworm.com/index.php?rid=1640367&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F341468289%2F Over the past month, Ranbaxy Laboratories agreed to be acquired by Daiichi Sankyo and then settled outstanding patent litigation with Pfizer over the Lipitor cholesterol pill. In response, The Business Standard spoke with Davinder Singh Brar, who led the generic drugmaker for several years until 2004 and now heads GVK BioSciences, a contract research organization, about the viability of the generic model. Standard: Is the Ranbaxy sale the way ahead for Indian pharmaceutical firms? Singh Brar: Most Indian companies have followed the business model that was evolved by Ranbaxy in the mid-1990s. After the Waxman-Hatch Act was registered in the US, there was a lot of growth in the generic business there. In some countries like India, product patents were not implemented and this led to the grow... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1640367 Mon, 21 Jul 2008 11:45:40 +0100 1640367 http://www.medworm.com/index.php?rid=1635185&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F338042342%2F Malvinder Singh is scrambling to play damage control over the US investigation into charges the generic drugmaker covered up a scheme to sell potentially adulterated meds, including AIDS pills. The news raised doubts about Daiichi Sankyo’s proposed $4.6 billion purchase of the Indian company, battering its stock. But Singh maintains the investigation was disclosed to Daiichi as part of the due diligence process and blames an unnamed big pharma and another Indian drugmaker for spreading rumors in order to unravel the deal. “There has been speculation in the market due to lack of understanding and we have information that a multinational and a leading Indian company are working in concert to bring our share price down. I have a clear sense of what is happening. People are trying to c... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1635185 Thu, 17 Jul 2008 13:13:06 +0100 1635185 http://www.medworm.com/index.php?rid=1631577&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F337980144%2F Hello again, everyone. And pardon the delay. A rodent entered the Pharmalot corporate campus without the required security clearance and had to be escorted from the premises. Now, though, we are back to business and, of course, preparing our usual cup of stimulation. Here is to a productive day… Daiichi Sankyo Confirms Plan To Buy Ranbaxy (Bloomberg News) Novartis Earnings Helped By Cost-Cutting (Bloomberg News) Abbott Earnings Helped By Humira Sales (Yahoo/AP) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1631577 Thu, 17 Jul 2008 11:40:31 +0100 1631577 http://www.medworm.com/index.php?rid=1625791&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F336983271%2F Hello, everyone. Here we are again. The middle of the week always means there is much to do. And our own routine holds no exceptions. So while we scurry about, here are a few items to help you ease in yourself. Good luck with whatever the day holds… Ranbaxy CEO Insists Daiichi Deal Is On Track (Bloomberg News) Diversification Pays Off For J&J (Forbes) States Claim Payouts In Bristol-Myers Settlement (Yahoo/AP) ViroPharma To Pay $443M For Lev Pharma (Yahoo/Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1625791 Wed, 16 Jul 2008 11:18:12 +0100 1625791 http://www.medworm.com/index.php?rid=1622997&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F335402869%2F Nothing like pressure from federal prosecutors to get a company to turn over documents. Earlier this month, the US Attorney in Maryland went to court to force the Indian generic drugmaker to release audits that may shed light on allegations Ranbaxy falsified records resulting in the production and sale of generic meds that didn’t meet FDA standards. Today, Ranbaxy filed its response and notes that it is now prepared to release the audits, which were conducted by Paraxel, and no longer claims attorney-client privilege as a reason for the audits to remain under wraps. At the same time, Ranbaxy maintains it “knows of no evidence to support (the) allegations,” but will cooperate with the government. Meanwhile, Ranbaxy released a statement saying its planned sale to Daiichi Sankyo... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1622997 Mon, 14 Jul 2008 20:22:26 +0100 1622997 http://www.medworm.com/index.php?rid=1543341&cid=t_188899_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F319955555%2Ffda_delays_prasugrel_approval.html Eli Lilly & Co and Daiichi Sankyo announced the U.S. Food and Drug Administration had extended the period of review by three months for their anti-clotting drug, Prasugrel.Prasugrel received priority review status from the FDA in February based on studies that showed Prasugrel has better results than Plavix but carried a higher risk of bleeding in some patients."We remain confident in our prasugrel submission package," said Jennifer Stotka, vice president for global regulatory affairs at Lilly.Daiichi and Lilly confirmed plans to start a Phase III clinical trial this month that will compare the results of prasugrel against Plavix in patients with acute coronary syndromes. The trials will consisted of 10,000 patients at over 800 hospitals.The FDA is expected to act on the... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1543341 Wed, 25 Jun 2008 18:00:38 +0100 1543341 http://www.medworm.com/index.php?rid=1509075&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F309556428%2F Japan’s third-largest drugmaker will get a 50.1 percent stake in India’s largest pharmaceutical company in a bid to diversify as government price cuts shrink margins and generics outpace brand-name meds. Malvinder Singh, Ranbaxy’s ceo, will remain in his job (pictured to the left). The move mimics Novartis, which operates the Sandoz unit that swallowed up two generic drugmakers in 2005 to reduce reliance on brand-name drugs. “Daiichi Sankyo’s strategy follows Novartis and it’s convincing,” Fumiyoshi Sakai, a health-care analyst at Credit Suisse Securities, tells Bloomberg News. “The essence of the deal is Daiichi Sankyo will seriously challenge generic business.” Price cuts in Japan mean that Daiichi Sankyo’s profit is likely to ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1509075 Wed, 11 Jun 2008 11:20:03 +0100 1509075 http://www.medworm.com/index.php?rid=1297935&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F250174672%2F We need an extra cup of stimulation this morning. We were so busy posting a gaggle of interesting items that we neglected to include our usually start-of-the-day greeting - it was queued up, but we never hit the send button. So sorry. Now, though, we believe we are on track, and we hope that you feel the same. To help you along, here are a few developments that caught our attention over the past few hours… Memory Cuts Workforce By 20 Percent (Press Release) AstraZeneca Faces August Trial For Seroquel Patent Dispute (Bloomberg News) ImClone Offered $32M In Rebates (The Star-Ledger of New Jersey) Daiichi-Sankyo Fails To Win FDA Approval For Anemia Med (Bloomberg News) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1297935 Wed, 12 Mar 2008 15:10:13 +0100 1297935 http://www.medworm.com/index.php?rid=1191572&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F226509147%2F Another day, another earnings report, or two. And who knows what else? As we assemble another interesting tale, we are also hunting and gathering all sorts of items. Here are a few for you. So grab your coffee or tea, or bottle of water, and catch up with the rest of us… AstraZeneca reported fourth-quarter profit declined as cutbacks and acquisition costs swelled while demand for its biggest meds slowed. Net income fell 12 percent to $1.3 billion, or 86 cents a share, from $1.43 billion, or 93 cents, a year earlier, while sales increased to $8.2 billion. The drugmaker is eliminating 7,600 jobs, or 11 percent of its workforce. Meanwhile, the Nexium heartburn med and the Crestor cholesterol pill slowed because of competition from cheaper generics, a trend that will be exacerbated by Wy... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1191572 Thu, 31 Jan 2008 12:13:34 +0100 1191572 http://www.medworm.com/index.php?rid=1166418&cid=t_188899_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F220604911%2Fwelchol_receives_fda_approval.html Daiichi Sankyo Inc. announced that it has received U.S. Food and Drug Administration approval for its drug Welchol that improves glycemic control when combined with metformin, sulfonylureas or insulin in patients with Type 2 diabetes.Welchol becomes the only FDA approved medication that reduces both glucose levels and low density lipoprotien cholesterol levels (LDL-C). The American Diabetes Association estimates that 40% of patients with Type 2 diabetes also have increased levels of LDL-C and Welchol affords the opportunity to treat both conditions with one medication."We are excited by the opportunity to help more patients with chronic conditions reach their recommended health goals," said Joseph P. Pieroni, President and CEO of Daiichi Sankyo, Inc. "This approval represent... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1166418 Mon, 21 Jan 2008 20:00:26 +0100 1166418 http://www.medworm.com/index.php?rid=814345&cid=t_188899_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F146526542%2F The rain is still falling heavily this morning in the nation’s medicine chest. So what better way to enjoy the comfort of the indoors than to catch up on events? Alpharma To Market First Topical Pain Patch (Yahoo/AP) Bayers Shares Rise - Again - On Novartis Merger Speculation (Bloomberg News) Lilly Seeks Cymbalta Approval For Fibromyalagia (Yahoo/Reuters) Forest Labs And Daiichi Sankyo To Co-Promote Blood Pressure Med (Yahoo/AP) Watons Wins FDA Approval For Generic Duragesic (Yahoo/Reuters) Wyeth Spends $50M To Expand North Carolina Plant (bizjournals.com) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=814345 Tue, 21 Aug 2007 14:16:06 +0100 814345 http://www.medworm.com/index.php?rid=624594&cid=t_188899_150_f&fid=35603&url=http%3A%2F%2Fdrugreptoys.blogspot.com%2F2007%2F04%2Fbenicar-post-it-notes.html Just basic post-it notes, tough to go wrong here. (Source: Drug Rep Toys) Drug Rep Toys blogs http://www.medworm.com/rss/comments.php?id=624594 Mon, 16 Apr 2007 04:22:00 +0100 624594